Top Medical News
Jairia Dela Cruz, an hour ago
The use of the third-generation Sapien device in transcatheter aortic valve implantation (TAVI) affords favourable short-term outcomes, with high success rates, low procedural complications and excellent postimplant haemodynamics, according to the results of the SOURCE 3* study.
17 hours ago
Patients with myotonic dystrophy type 1 (DM1) have elevated levels of plasma cardiac troponin-I (cTnI), a new study shows.
Roshini Claire Anthony, 21 hours ago

The use of uninterrupted dabigatran before, during, and after catheter ablation in patients with atrial fibrillation (AF) resulted in fewer major bleeding complications than uninterrupted warfarin, according to results of the RE-CIRCUIT* trial.

Audrey Abella, Yesterday
Fertility treatment failure was associated with an increased risk of long-term adverse cardiovascular (CV) events, according to data from the INFERTILE* study.
Pearl Toh, Yesterday
Transcatheter aortic valve replacement (TAVR) is an effective and safe alternative to surgical aortic valve replacement (SAVR) for intermediate- and high-risk patients in the real world, with no significant difference in stroke and mortality rates at 1 year, and discharge to home being more common among TAVR patients, according to the ADVICE* study presented at the recent ACC.17 Scientific Session held in Washington, DC, US.
Elaine Soliven, Yesterday

Noninvasive magnetic resonance (MR) perfusion imaging may be effective as initial guided management in patients with stable angina and intermediate-to-high risk for coronary artery disease (CAD) compared with invasive angiography and fractional flow reserve (FFR), according to the MR-INFORM* trial presented at the American College of Cardiology’s 66th Annual Scientific Session (ACC.17) held in Washington, DC, US.

Yesterday
Podcast: Dr Michael Reardon speaks on how the self-expanding TAVR is noninferior to SAVR in intermediate-risk AS patients in the SURTAVI trial.
Special Reports
16 Mar 2017
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
07 Mar 2017
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
16 Feb 2017
At the recent launch of an exclusive guidebook on vasodilating β-blockers for the treatment of hypertension and chronic heart failure (HF), Professor Athanasios J. Manolis delivered a lecture on why nebivolol is different from the other agents in its class.
16 Dec 2016
During the 8th Diabetes Complications Conference & Grand Rounds 2016, Dr Azani Mohamed Daud talked about the guidelines on the use of ACEIs and ARBs in hypertension, and highlighted their clinical efficacies for hypertension treatment.
Prof. Abdul Rashid, Prof. Martin Strauss, Prof. Alistair Hall, 12 Dec 2016
Hypertension is a leading cause of mortality globally and is of particular concern in the Asia Pacific region where there are more deaths due to poor blood pressure (BP) control than in any other region in the world. At a recent Servier-sponsored satellite symposium held during the ASEAN Federation of Cardiology Congress in Yangon, Myanmar, Professor Abdul Rashid, An Nur Specialist Hospital, Selangor, Malaysia, discussed the challenges associated with managing hypertension in the region. In addition, Professor Martin Strauss, North York General Hospital, Toronto, Canada and Professor Alistair Hall, Leeds General Infirmary, UK, discussed the different effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) outcomes, highlighting the additional protection against myocardial infarction (MI) offered by ACE inhibitors such as perindopril.
Pearl Toh, 07 Dec 2016
Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.
Roshini Claire Anthony, 25 Nov 2016

The addition of evolocumab to statin therapy in individuals with angiographic coronary disease appeared to encourage coronary atherosclerosis regression, as demonstrated in the GLAGOV* trial presented at the Scientific Sessions of the American Heart Association (AHA 2016) held in New Orleans, Louisiana, US.

Conference Reports
Pearl Toh, 28 Mar 2017
Transcatheter aortic valve replacement (TAVR) is an effective and safe alternative to surgical aortic valve replacement (SAVR) for intermediate- and high-risk patients in the real world, with no significant difference in stroke and mortality rates at 1 year, and discharge to home being more common among TAVR patients, according to the ADVICE* study presented at the recent ACC.17 Scientific Session held in Washington, DC, US.
Elaine Soliven, 28 Mar 2017

Noninvasive magnetic resonance (MR) perfusion imaging may be effective as initial guided management in patients with stable angina and intermediate-to-high risk for coronary artery disease (CAD) compared with invasive angiography and fractional flow reserve (FFR), according to the MR-INFORM* trial presented at the American College of Cardiology’s 66th Annual Scientific Session (ACC.17) held in Washington, DC, US.

28 Mar 2017
Podcast: Dr Michael Reardon speaks on how the self-expanding TAVR is noninferior to SAVR in intermediate-risk AS patients in the SURTAVI trial.
28 Mar 2017
Podcast: Dr Marc Sabatine talks about the FOURIER Outcomes trial which shows lower CV events with the PCSK9 inhibitor evolocumab.
28 Mar 2017
Slideshow: Highlights from the American College of Cardiology 66th Annual Scientific Session (ACC)
Pearl Toh, 27 Mar 2017
Extended therapy with rivaroxaban was more effective than aspirin in reducing the risk of recurrent venous thromboembolism (VTE) with no significant increase in bleeding risk, according to data from the EINSTEIN CHOICE* study presented at the ACC.17 Scientific Session in Washington, DC, US.
Pearl Toh, 25 Mar 2017
Treatment with inclisiran, a siRNA for PCSK9 knockdown, delivers significant and sustained LDL-C lowering in a dose-dependent manner over 6 to 9 months in patients with high cardiovascular (CV) risk, according to the ORION-1* study presented at the ACC.17 Scientific Session held in Washington, DC, US.
Product Highlights
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD